Archive WILEX Ad-hoc- and Press Releases before 2003

Selected press releases of the former years can be found here.

2009 2008 2007 2006 2005 2004 2003 before 2003
28 November 2002
Study on clinical Phase II trial with antibody cG250 against renal cell carcinoma receives Clinical Science Award 2002
20 November 2002
WILEX receives Drug Manufacturing Permission and international GLP certification from German authorities (German only)
14 October 2002
WILEX initiates first clinical trial for Urokinase Inhibitor WX-UK1 in cancer patients
09 April 2002
WILEX’s WX-G250 renal cancer therapeutic shows clinical benefit in Phase II trial
08 April 2002
WILEX receives Orphan Drug Designation in Europe for WX-G250
18 March 2002
WILEX reports positive Phase Ia clinical data on its anti-metastatic Urokinase Inhibitor WX-UK1
04 March 2002
WILEX appoints members to its Scientific Advisory Board

2001
12 November 2001
WILEX AG and Bayer Corporation sign license, sublicense and option agreement
20 September 2001
WILEX starts Phase I trial with anti-metastatic Urokinase Inhibitor Drug
1 June 2001
WILEX’s cancer drug receives Orphan Drug Designation
18 May 2001
WILEX and LICR report results from completed Phase I trial of cG250 in renal cancer patients

2000
13 November 2000
WILEX completes Euro 30 Million financing to advance cancer programs
22 May 2000
WILEX appoints Vice President Business Development

1999
31 August 1999
WILEX licences antibody for renal cancer
14 April 1999
WILEX appoints Professor Sven Warnaar as Vice-President of Oncology
4 March 1999
WILEX receives DM 1.8 Million BioRegio Grant

Print This Page Print This Page | Email This Page Email This Page    
Seite gelesen: 68 | Heute: 3